Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | polo-like kinase 1 | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0116 | 0.1136 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0784 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0329 | 0.0329 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0116 | 0.1136 | 1 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0116 | 0.1136 | 0.0835 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0116 | 0.1136 | 0.0835 |
Schistosoma mansoni | kinase | 0.006 | 0.0392 | 0.0065 |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.0784 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0116 | 0.1136 | 1 |
Brugia malayi | serine/threonine-protein kinase plk-2 | 0.0116 | 0.1136 | 0.1136 |
Trypanosoma brucei | polo-like protein kinase | 0.0116 | 0.1136 | 1 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.0784 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0116 | 0.1136 | 0.0835 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.0784 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0116 | 0.1136 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0329 | 0.0329 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0116 | 0.1136 | 0.1136 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0116 | 0.1136 | 0.5 |
Giardia lamblia | Kinase, PLK | 0.0116 | 0.1136 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0116 | 0.1136 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2239 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.2387 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.8336 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.